Skip to content

Advertisement

Articles

Page 1 of 1

  1. Content type: Review

    The scenario of multiple sclerosis (MS) treatment has changed profoundly in recent decades. In this setting, one of two strategies is usually used: escalation or induction. The first involves a pyramid of poss...

    Authors: Serena Ruggieri, Simona Pontecorvo, Carla Tortorella and Claudio Gasperini

    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:5

    Published on:

  2. Content type: Research article

    There are few reports about the actual state of diagnosis for multiple sclerosis (MS) in Japan. In addition, in late years multiple disease-modifying drugs (DMDs) were released in Japan, but there are few repo...

    Authors: Katsutoshi Hiramatsu, Masakazu Hase and Hirofumi Ochi

    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:4

    Published on:

  3. Content type: Research article

    Treatment algorithms for neuromyelitis optica spectrum disorder (NMOSD) vary, and sparse data exist regarding the impact of initial treatments on disease course. We aimed to determine whether administration of...

    Authors: Sabrina Gmuca, Rui Xiao, Pamela F. Weiss, Amy T. Waldman and Jeffrey S. Gerber

    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:3

    Published on:

  4. Content type: Review

    Multiple sclerosis (MS) is increasingly recognized in the paediatric age. In a smaller, but well-established, proportion of paediatric MS patients [20% of total paediatric MS cases: 0.2% to 0.7% of the total MS p...

    Authors: Vincenzo Salpietro, Agata Polizzi, Gaia Recca and Martino Ruggieri

    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:2

    Published on:

  5. Content type: Review

    Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patie...

    Authors: Alice Favaretto, Andrea Lazzarotto, Monica Margoni, Davide Poggiali and Paolo Gallo

    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:1

    Published on:

  6. Content type: Case report

    First recognized at the beginning of twentieth century and named after three authors who independently described some affected patients, Vogt-Koyanagi-Harada syndrome is a rare multisystemic autoimmune disease...

    Authors: Marta Scarioni, Anna M. Pietroboni, Alessandro Invernizzi, Francesco Viola, Laura Ghezzi, Alberto Calvi, Tiziana Carandini, Milena De Riz, Daniela Galimberti and Elio Scarpini

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:14

    Published on:

  7. Content type: Review

    Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a very high economic impact. Peginterferon beta-1a is the first approved pegylated interferon beta-1a for the treatm...

    Authors: Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani and Pier Luigi Canonico

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:13

    Published on:

  8. Content type: Short report

    To assess the association between objective bladder function parameters in relation to urinary symptoms, and to analyze the sensitivity and specificity of subjective urinary symptom-assessment in predicting ob...

    Authors: Shalom Haggiag, Giovanni Bolla, Orietta Picconi, Simonetta Galgani and Claudio Gasperini

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:11

    Published on:

  9. Content type: Research article

    Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS). Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered ...

    Authors: Paolo Ragonese, Paolo Aridon, Sabrina Realmuto, Giulia Vazzoler, Simona Alessi, Erika Portera, Alessia Bianchi, Fabio Triolo, Maria Antonietta Mazzola, Marco D’Amelio, Giovanni Savettieri and Giuseppe Salemi

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:12

    Published on:

  10. Content type: Research article

    We prospectively assessed the influence of JCV- status on disability’s accrual in RRMS patients treated with Natalizumab at two tertiary MS centres, settled in Italy.

    Authors: E. D’Amico, A. Zanghì, A. Signori, LME Grimaldi and F. Patti

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:9

    Published on:

  11. Content type: Research article

    Fingolimod is an efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) and there is class I evidence that it is superior to standard care in reducing relapse rate. However, real-world data in...

    Authors: Manuela Giuliani, Alessandra Logoteta, Luca Prosperini, Maria Neve Hirsch and Carlo Pozzilli

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:10

    Published on:

  12. Content type: Review

    Cognitive dysfunction is frequent in multiple sclerosis patients and has important and negative consequences for daily activities and quality of life of subjects. Disease modifying treatments for multiple scle...

    Authors: Claudia Niccolai, Benedetta Goretti and Maria Pia Amato

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:8

    Published on:

  13. Content type: Review

    Alemtuzumab (Lemtrada®) is a humanized anti-CD52 IgG1 monoclonal antibody that depletes CD52-expressing cells from the circulation. Robust clinical and radiologic data, derived from clinical trials and long-te...

    Authors: Paolo Gallo, Diego Centonze and Maria Giovanna Marrosu

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:7

    Published on:

  14. Content type: Review

    In this review the most important aspects of pediatric multiple sclerosis are presented and compared with the adult form. Some findings appear peculiar of pediatric MS:

    a.
     

    Authors: Angelo Ghezzi, Damiano Baroncini, Mauro Zaffaroni and Giancarlo Comi

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:5

    Published on:

  15. Content type: Case report

    Along with vitamin D, smoking, body mass index and others, Epstein Barr virus, other herpesviruses and human endogenous retroviruses represent plausible environmental risk factors for multiple sclerosis. Howev...

    Authors: M. C. Buscarinu, A. Fornasiero, S. Romano, M. Ferraldeschi, R. Renié, G. Trasimeni, M. Salvetti and G. Ristori

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:6

    Published on:

  16. Content type: Research article

    Methylthioadenosine is a metabolite of the polyamine pathway that modulates methyltransferase activity, thereby influencing DNA and protein methylation. Since methylthioadenosine produces neuroprotection in mo...

    Authors: Beatriz Moreno, Gemma Vila, Begoña Fernandez-Diez, Raquel Vázquez, Alessandra di Penta, Oihana Errea, Nagore Escala, Andrés Miguez, Jordi Alberch and Pablo Villoslada

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:3

    Published on:

  17. Content type: Research article

    Despite intense research, the causes of various neurological diseases remain enigmatic to date. A role for viral or bacterial infection and associated molecular mimicry has frequently been suggested in the eti...

    Authors: Jussi Tuusa, Arne Raasakka, Salla Ruskamo and Petri Kursula

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:4

    Published on:

  18. Content type: Review

    Cognitive impairment is very frequent during multiple sclerosis (MS), involving approximately 40–70% of the patients, with a profound impact on patient’s life. It is now established that among the various cent...

    Authors: Andrea Mancini, Lorenzo Gaetani, Maria Di Gregorio, Alessandro Tozzi, Veronica Ghiglieri, Paolo Calabresi and Massimiliano Di Filippo

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:2

    Published on:

  19. Content type: Research article

    Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in...

    Authors: Cristina Scarpazza, Nicola De Rossi, Lucia Moiola, Simonetta Gerevini, Mirco Cosottini, Ruggero Capra and Flavia Mattioli

    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:1

    Published on:

  20. Content type: Research article

    The immunopathogenesis of pediatric multiple sclerosis (MS) is not well understood.

    Authors: Vikram Bhise, Konstantin Balashov, Marc Sturgill, Lauren Krupp and Suhayl Dhib-Jalbut

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:15

    Published on:

  21. Content type: Research article

    Immediately following immunoablation and hematopoietic stem cell transplantation (IA-HSCT) for MS a median decrease in brain volume of 3.2 % over 2.4 months occurs. After 2 years, rates of atrophy are comparab...

    Authors: Lisa A. S. Walker, Jason A. Berard, Marjorie Bowman, Harold L. Atkins, Hyunwoo Lee, Douglas Arnold and Mark S. Freedman

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:12

    Published on:

  22. Content type: Review

    Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unkn...

    Authors: Lina Hassoun, Judith Eisele, Katja Thomas and Tjalf Ziemssen

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:10

    Published on:

  23. Content type: Review

    Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without unequivocal recovery. Understanding the mechanisms that determine entering in this stage o...

    Authors: Fernando Pérez-Cerdá, María Victoria Sánchez-Gómez and Carlos Matute

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:9

    Published on:

  24. Content type: Case Report

    Natalizumab is highly effective in reducing multiple sclerosis disease activity; however it carries a risk of progressive multifocal leukoencephalopathy, that represents the main reason of drug discontinuation...

    Authors: Simona Malucchi, Marco Capobianco, Alessia di Sapio, Marianna Lo Re, Paola Cavalla and Antonio Bertolotto

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:11

    Published on:

  25. Content type: Review

    Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous system. Treatment of MS involves disease-modifying therapies (DMTs) to reduce the incidence of relapses and pr...

    Authors: Giancarlo Comi, Maria Pia Amato, Antonio Bertolotto, Diego Centonze, Nicola De Stefano, Cinthia Farina, Paolo Gallo, Angelo Ghezzi, Luigi Maria Grimaldi, Gianluigi Mancardi, Maria Giovanna Marrosu, Enrico Montanari, Francesco Patti, Carlo Pozzilli, Leandro Provinciali, Marco Salvetti…

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:6

    Published on:

  26. Content type: Research article

    We aim to identify differentially expressed genes (DEGs) and its pathways associated with clinical activity of relapsing–remitting Multiple Sclerosis (RRMS).

    Authors: Ion Agirrezabal, Ricardo Palacios, Beatriz Moreno, Jorge Sepulcre, Alice Abernathy, Albert Saiz, Sara Llufriu, Manuel Comabella, Xavier Montalban, Antonio Martinez, David Arteta and Pablo Villoslada

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:7

    Published on:

  27. Content type: Review

    The discovery that several demyelinating disorders in children may be associated with autoantibodies to astrocytes, myelin, and/or synaptic proteins has opened the possibility of their use as diagnostic and pr...

    Authors: Thaís Armangue, Anusha K. Yeshokumar, Maria Sepúlveda, Francesc Graus and Albert Saiz

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:5

    Published on:

  28. Content type: Research article

    Dysfunction of higher cognitive abilities occurs in 40–60 % of people with multiple sclerosis (MS), as detected with neuropsychological testing, with predominant involvement of executive functions and processi...

    Authors: N. Amato, M. Cursi, M. Rodegher, L. Moiola, B. Colombo, M. Falautano, F. Possa, G. Comi, V. Martinelli and L. Leocani

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:8

    Published on:

  29. Content type: Review

    The increasing amount of highly effective treatment options in relapsing forms of multiple sclerosis (MS) requires innovative clinical trial design strategies. These strategies may encompass the application of...

    Authors: Manolo E. Beelke, Paola Antonini and Michael F. Murphy

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:2

    Published on:

  30. Content type: Research article

    The most suitable setting of rehabilitation for Persons with Multiple Sclerosis (PwMS) has not been identified so far because there is a general lacking of controlled studies. Aim of this study was to evaluate...

    Authors: Angelo Pappalardo, Emanuele D’Amico, Carmela Leone, Silvia Messina, Clara Chisari, L. Rampello, Lina Torre and Francesco Patti

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:3

    Published on:

  31. Content type: Research article

    Fingolimod is approved by EMA as a second-line treatment for relapsing-remitting multiple sclerosis (RRMS). Experience with fingolimod in real life is still limited. Aim of our study was to report data on fing...

    Authors: D. Baroncini, M. Zaffaroni, P. O. Annovazzi, S. Baldini, A. Bianchi, G. Minonzio, G. Comi and A. Ghezzi

    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:4

    Published on:

2017 Journal Metrics

  • Speed
    62 days from submission to first decision
    116 days from submission to acceptance
    17 days from acceptance to publication

    Usage 
    36,317 Downloads
    6 Altmetric Mentions

Advertisement